A pilot study on the impact of dopamine, serotonin, and brain-derived neurotrophic factor genotype on long-term functional outcomes after subarachnoid hemorrhage

Objectives: Many that survive an aneurysmal subarachnoid hemorrhage experience lasting physical disability, which might be improved by medications with effects on the dopaminergic, serotonergic, and brain-derived neurotrophic factor neurotransmitter systems. But it is not clear which patients are mo...

Full description

Bibliographic Details
Main Authors: Ansley Stanfill, Claire Simpson, Paula Sherwood, Samuel Poloyac, Elizabeth Crago, Hyungsuk Kim, Yvette Conley
Format: Article
Language:English
Published: SAGE Publishing 2017-08-01
Series:SAGE Open Medicine
Online Access:https://doi.org/10.1177/2050312117726725
id doaj-8452780d467c42cfb24b6e63b3391b67
record_format Article
spelling doaj-8452780d467c42cfb24b6e63b3391b672020-11-25T01:27:33ZengSAGE PublishingSAGE Open Medicine2050-31212017-08-01510.1177/2050312117726725A pilot study on the impact of dopamine, serotonin, and brain-derived neurotrophic factor genotype on long-term functional outcomes after subarachnoid hemorrhageAnsley Stanfill0Claire Simpson1Paula Sherwood2Samuel Poloyac3Elizabeth Crago4Hyungsuk Kim5Yvette Conley6Department of Genetics, Genomics and Informatics, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USADepartment of Genetics, Genomics and Informatics, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USAAcute & Tertiary Care, School of Nursing, University of Pittsburgh, Pittsburgh, PA, USASchool of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USAAcute & Tertiary Care, School of Nursing, University of Pittsburgh, Pittsburgh, PA, USANational Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USADepartment of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USAObjectives: Many that survive an aneurysmal subarachnoid hemorrhage experience lasting physical disability, which might be improved by medications with effects on the dopaminergic, serotonergic, and brain-derived neurotrophic factor neurotransmitter systems. But it is not clear which patients are most likely to benefit from these therapies. The purpose of this pilot study was to explore the relationship of genetic polymorphisms in these pathways with 12-month functional outcomes after aneurysmal subarachnoid hemorrhage. Methods: Subjects were recruited at the time of admission as a part of a larger parent study. Genotypes were generated using the Affymetrix genome-wide human single-nucleotide polymorphism array 6.0. Those within dopaminergic, serotonergic, and brain-derived neurotrophic factor pathways were analyzed for associations with functional outcomes at 12 months post aneurysmal subarachnoid hemorrhage using the Glasgow Outcome Scale and the Modified Rankin Scale. Results: The 154 subjects were 55.8 ± 11.3 years old and 74% female; they had Fisher scores of 2.95 ± 0.67, Hunt/Hess scores of 2.66 ± 1.13, and admission Glasgow Coma Scale scores of 12.52 ± 3.79. Single-nucleotide polymorphisms in the serotonin receptor genes 1B and 1E and dopamine receptor D2 were associated with greater disability (odds ratio: 3.88–3.25, confidence interval: 1.01–14.77), while single-nucleotide polymorphisms in the serotonin receptor genes 2A and 2C and dopamine receptor D5 conferred a risk of poor recovery (odds ratio: 3.31–2.32, confidence interval: 1.00–10.80). Single-nucleotide polymorphisms within the same serotonin genes, and within the dopamine receptor gene D2, were associated with greater recovery after aneurysmal subarachnoid hemorrhage (odds ratio: 0.17–0.34, confidence interval: 0.05–0.89). Conclusions: These data demonstrate that there may be an association between genetic factors and functional outcomes post stroke.https://doi.org/10.1177/2050312117726725
collection DOAJ
language English
format Article
sources DOAJ
author Ansley Stanfill
Claire Simpson
Paula Sherwood
Samuel Poloyac
Elizabeth Crago
Hyungsuk Kim
Yvette Conley
spellingShingle Ansley Stanfill
Claire Simpson
Paula Sherwood
Samuel Poloyac
Elizabeth Crago
Hyungsuk Kim
Yvette Conley
A pilot study on the impact of dopamine, serotonin, and brain-derived neurotrophic factor genotype on long-term functional outcomes after subarachnoid hemorrhage
SAGE Open Medicine
author_facet Ansley Stanfill
Claire Simpson
Paula Sherwood
Samuel Poloyac
Elizabeth Crago
Hyungsuk Kim
Yvette Conley
author_sort Ansley Stanfill
title A pilot study on the impact of dopamine, serotonin, and brain-derived neurotrophic factor genotype on long-term functional outcomes after subarachnoid hemorrhage
title_short A pilot study on the impact of dopamine, serotonin, and brain-derived neurotrophic factor genotype on long-term functional outcomes after subarachnoid hemorrhage
title_full A pilot study on the impact of dopamine, serotonin, and brain-derived neurotrophic factor genotype on long-term functional outcomes after subarachnoid hemorrhage
title_fullStr A pilot study on the impact of dopamine, serotonin, and brain-derived neurotrophic factor genotype on long-term functional outcomes after subarachnoid hemorrhage
title_full_unstemmed A pilot study on the impact of dopamine, serotonin, and brain-derived neurotrophic factor genotype on long-term functional outcomes after subarachnoid hemorrhage
title_sort pilot study on the impact of dopamine, serotonin, and brain-derived neurotrophic factor genotype on long-term functional outcomes after subarachnoid hemorrhage
publisher SAGE Publishing
series SAGE Open Medicine
issn 2050-3121
publishDate 2017-08-01
description Objectives: Many that survive an aneurysmal subarachnoid hemorrhage experience lasting physical disability, which might be improved by medications with effects on the dopaminergic, serotonergic, and brain-derived neurotrophic factor neurotransmitter systems. But it is not clear which patients are most likely to benefit from these therapies. The purpose of this pilot study was to explore the relationship of genetic polymorphisms in these pathways with 12-month functional outcomes after aneurysmal subarachnoid hemorrhage. Methods: Subjects were recruited at the time of admission as a part of a larger parent study. Genotypes were generated using the Affymetrix genome-wide human single-nucleotide polymorphism array 6.0. Those within dopaminergic, serotonergic, and brain-derived neurotrophic factor pathways were analyzed for associations with functional outcomes at 12 months post aneurysmal subarachnoid hemorrhage using the Glasgow Outcome Scale and the Modified Rankin Scale. Results: The 154 subjects were 55.8 ± 11.3 years old and 74% female; they had Fisher scores of 2.95 ± 0.67, Hunt/Hess scores of 2.66 ± 1.13, and admission Glasgow Coma Scale scores of 12.52 ± 3.79. Single-nucleotide polymorphisms in the serotonin receptor genes 1B and 1E and dopamine receptor D2 were associated with greater disability (odds ratio: 3.88–3.25, confidence interval: 1.01–14.77), while single-nucleotide polymorphisms in the serotonin receptor genes 2A and 2C and dopamine receptor D5 conferred a risk of poor recovery (odds ratio: 3.31–2.32, confidence interval: 1.00–10.80). Single-nucleotide polymorphisms within the same serotonin genes, and within the dopamine receptor gene D2, were associated with greater recovery after aneurysmal subarachnoid hemorrhage (odds ratio: 0.17–0.34, confidence interval: 0.05–0.89). Conclusions: These data demonstrate that there may be an association between genetic factors and functional outcomes post stroke.
url https://doi.org/10.1177/2050312117726725
work_keys_str_mv AT ansleystanfill apilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT clairesimpson apilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT paulasherwood apilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT samuelpoloyac apilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT elizabethcrago apilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT hyungsukkim apilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT yvetteconley apilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT ansleystanfill pilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT clairesimpson pilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT paulasherwood pilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT samuelpoloyac pilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT elizabethcrago pilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT hyungsukkim pilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
AT yvetteconley pilotstudyontheimpactofdopamineserotoninandbrainderivedneurotrophicfactorgenotypeonlongtermfunctionaloutcomesaftersubarachnoidhemorrhage
_version_ 1725104730039910400